Vesicular stomatitis virus infection triggers apoptosis associated with decreased ΔNp63α and increased Bax levels in the immortalized HaCaT keratinocyte cell line

Biomedicine and Pharmacotherapy

Volumn 61, Issue 5, 2007, Pages 254-260

  Megyeri, Klára ^a   Orosz, László ^a   Kemény, Lajos ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Apoptosis; HaCaT cell line; Vesicular stomatitis virus

Indexed keywords

MUTANT PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN DELTA NP63ALPHA; PROTEIN P18; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KERATINOCYTE; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA VIRUS INFECTION; VESICULAR STOMATITIS VIRUS; VIRUS PLAQUE; VIRUS REPLICATION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE; CELL LINE, TRANSFORMED; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KERATINOCYTES; MUTATION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 34250006546     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.03.006     Document Type: Article

References (49)

1. Tsao H. Genetics of nonmelanoma skin cancer. Arch Dermatol 137 (2001) 1486-1492
2. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression?. Carcinogenesis 26 (2005) 1657-1667
3. Tilli C.M.L.J., Van Steensel M.A.M., Krekels G.A.M., Neumann H.A.M., and Ramaekers F.C.S. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 152 (2005) 1108-1124
4. Bäckvall H., Asplund A., Gustafsson A., Sivertsson Å., Lundeberg J., and Ponten F. . Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res 571 (2005) 65-79
5. Albright III S.D. Treatment of skin cancer using multiple modalities. J Am Acad Dermatol 7 (1982) 143-171
6. Telfer N.R., Colver G.B., and Bower P.W. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 141 (1999) 415-423
7. Thissen M.R., Schroeter C.A., and Neumann H.A. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 142 (2000) 338-339
8. Peris K., Campione E., Micantonio T., Marulli G.C., Fargnoli M.C., and Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 31 (2005) 318-323
9. Megyeri K., Au W.-C., Rosztóczy I., Raj N.B.K., Miller R.L., Tomai M.A., et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 15 (1995) 2207-2218
10. Schön M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95 (2003) 1138-1149
11. Mathé G. Genes galore. Biomed Pharmacother 54 (2000) 475-478
12. Ring C.J.A. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83 (2002) 491-502
13. Biederer C., Ries S., Brandts C.H., and McCormick F. Replication-selective viruses for cancer therapy. J Mol Med 80 (2002) 163-175
14. Verma I.M., and Weitzman M.D. Gene therapy: twenty-first century medicine. Annu Rev Biochem 74 (2005) 711-738
15. Rose J.K., and Whitt M.A. Rhabdoviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 1221-1242
16. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., and Sonenberg N. et al Exploiting tumor-specific defects in the interferon pathway with previously unknown oncolytic virus. Nat Med 6 (2000) 821-825
17. Balachandran S., Porosnicu M., and Barber G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol 75 (2001) 3474-3479
18. Fernandez M., Porosnicu M., Markovic D., and Barber G.N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76 (2002) 895-904
19. Stojdl D.F., Lichty B.D., tenOver B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell 4 (2003) 263-275
20. Obuchi M., Fernandez M., and Barber G.N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 77 (2003) 8843-8856
21. Balachandran S., and Barber G.N. Defective translation control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5 (2004) 51-65
22. Lichty B.D., Power A.T., Stojdl D.F., and Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10 (2004) 210-216
23. Lichty B.D., Stojdl D.F., Taylor R.A., Miller L., Frenkel I., Atkins H., et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 15 (2004) 821-831
24. Masters P.S., and Samuel C.E. Mechanism of interferon action: Inhibition of vesicular stomatitis virus replication in human amnion U cells by cloned human leukocyte interferon. II Effect on viral macromolecular synthesis. J Biol Chem 258 (1983) 12026-12033
25. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 74 (2000) 9580-9585
26. Gallyas E., Seprényi G., Sonkoly E., Mándi Y., Kemény L., and Megyeri K. Vesicular stomatitis virus induces apoptosis in the Wong-Kilbourne derivative of the Chang conjunctival cell line. Graefe's Arch Clin Exp Ophthalmol 244 (2006) 717-724
27. Gaddy D.F., and Lyles D.S. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 79 (2005) 4170-4179
28. Kopecky S.A., Willingham M.C., and Lyles D.S. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 75 (2001) 12169-12181
29. Gadaleta P., Perfetti X., Mersich S., and Coulombié F. Early activation of the mitochondrial apoptotic pathway in vesicular stomatitis virus-infected cells. Virus Res 109 (2005) 65-69
30. Hobbs J.A., Schloemer R.H., Hommel-Berrey G., and Brahmi Z. Caspase-3-like proteases are activated by infection but are not required for replication of vesicular stomatitis virus. Virus Res 80 (2001) 53-65
31. Hobbs J.A., Hommel-Berrey G., and Brahmi Z. Requirement of caspase-3 for efficient apoptosis induction and caspase-7 activation but not viral replication or cell rounding in cells infected with vesicular stomatitis virus. Hum Immunol 64 (2003) 82-92
32. Kopecky S.A., and Lyles D.S. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 77 (2003) 5524-5528
33. Kopecky S.A., and Lyles D.S. Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol 77 (2003) 4658-4669
34. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornug J., Markham A., and Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106 (1988) 761-771
35. Fusenig N.E., and Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 23 (1998) 144-158
36. Chen X., Ko L.J., Jayaraman L., and Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10 (1996) 2438-2451
37. Sheikh M.S., and Fornace A.J. Role of p53 family members in apoptosis. J Cell Physiol 182 (2000) 171-181
38. Levrero M., De Laurenzi V., Costanzo A., Sabatini S., Gong J., and Wang J.Y.J. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113 (2000) 1661-1670
39. Irwin M.S., and Kaelin W.G. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12 (2001) 337-349
40. Gressner O., Schilling T., Lorenz K., Schulze Schleithoff E., Koch A., Schulze-Bergkamen H., et al. TAp63α induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24 (2005) 2458-2471
41. Koster M.I., and Roop D.R. The role of p63 in development and differentiation of the epidermis. J Dermatol Sci 34 (2004) 3-9
42. Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I., Bondanza S., et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 98 (2001) 3156-3161
43. Barbieri C.E., and Pietenpol J.A. p63 and epithelial biology. Exp Cell Res 312 (2006) 695-706
44. Davison T.S., Vagner C., Kaghad M., Ayed A., Caput D., and Arrowsmith C.H. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274 (1999) 18709-18714
45. Gaiddon C., Lokshin M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21 (2001) 1874-1887
46. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277 (2002) 18817-18826
47. Urist M.J., Di Como C.J., Lu M.-L., Charytonowicz E., Verbel D., Crum C.P., et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161 (2002) 1199-1206
48. Westfall M.D., Mays D.J., Sniezek J.C., and Pietenpol J.A. The ΔNp63α phosphoprotein binds the p21 and 14-3-3σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23 (2003) 2264-2276
49. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39 (2003) 615-647